Frazier Life Sciences Management’s Ascendis Pharma A/S ASND Stock Holding History

Frazier Life Sciences Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$60.1M	Buy	225,155 +91,822	+69%	+$21.4M	1.31%	15
2026 Q1	$30.5M	Hold	133,333	–	–	0.78%	25
2025 Q4	$28.4M	Hold	133,333	–	–	0.76%	27
2025 Q3	$26.5M	Hold	133,333	–	–	0.79%	28
2025 Q2	$23M	Hold	133,333	–	–	0.92%	23
2025 Q1	$20.8M	Hold	133,333	–	–	0.95%	21
2024 Q4	$18.4M	Hold	133,333	–	–	0.76%	27
2024 Q3	$19.9M	Buy	+133,333	New	+$18M	0.8%	28

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Frazier Life Sciences Management's ASND Position: Q2 2026 in Review

Frazier Life Sciences Management increased its Ascendis Pharma A/S (ASND) stake by 69% in Q2 2026, buying an estimated $21.4M and bringing the position to 225,155 shares worth $60.1M. The position accounts for 1.31% of the portfolio, ranked #15.

Frazier Life Sciences Management first reported a position in ASND in Q3 2024 and has held it in 8 quarters since. 311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Frazier Life Sciences Management held 225,155 shares of Ascendis Pharma A/S worth $60.1M as of Q2 2026.
Frazier Life Sciences Management bought 91,822 Ascendis Pharma A/S shares in Q2 2026, an estimated $21.4M.
Ascendis Pharma A/S made up 1.31% of Frazier Life Sciences Management's portfolio in Q2 2026, its #15 holding.
Frazier Life Sciences Management first reported a position in Ascendis Pharma A/S in Q3 2024 and has held it in 8 quarters since.
311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Frazier Life Sciences Management's 13F filing for Q2 2026, filed 14 Aug 2026.